经历第1 代和第2 代疫苗失败磨难后的人类免疫缺陷病毒( HI V) 疫苗领域, 终于在漫漫征途中看到了一线曙光。第1 、2 代联合疫苗在泰国开展RV144 Ⅲ期临床试验, 首次显示预防HI V 感染的目标并非遥不可及。更为广谱的中和抗体及其晶体结构的获得、抗体基因的直接导入产生的免疫保护、嵌合型T 细胞表位疫苗和复制型病毒载体疫苗的推进, 为产生较RV144 保护效果更好的疫苗提供了技术和策略支持。在国家科技重大专项的支持下, 中国HI V 疫苗联盟在合作攻关中推进创新性HIV 疫苗的研究。全球和地区层面的科技合作, 为中国HIV 疫苗研究提供了实现跨越式发展的历史性机遇。

After having gone through the bumpy road of the failure of first and second generations of human immunodeficiency virus ( HI V) vaccines , the first beamjust appeared recently . The goal of preventing HIV acquisitionis not unachievable , showing in the combined vaccine trial ( RV144) conducted in Thailand . With the progresses of obtaining better broad-spectrumneutralizing antibody and the development of its rystal structure , full protection achieved by genetic transferring of neutralizing antibodies , mosaic T cell epitope vaccines , as well as replicating viral vector vaccines , it is possible to achieve higher efficacy of vaccine protection. With the support of National Science and Technology Key Projects , scientists in the China HIV Vaccine Initiative are conducting innovative HI V vaccine research and also possible to make a big leap f orward , if seized the opportunity of international collaboration at the global and regional level .